29 results
8-K
EX-99.1
NTIP
Network-1 Technologies Inc
6 Sep 23
Other Events
4:36pm
objectives include demonstration of safety, nasal mucosal and serum immunological response, functional serum bactericidal activity, and reduction … of vaccine-related treatment-emergent adverse events was comparable between the BPZE1 and placebo groups, and there were no unexpected safety findings
8-K
NTIP
Network-1 Technologies Inc
30 Sep 20
Other Events
4:54pm
vaccine, met both primary endpoints of overall safety and induction of mucosal immunity. Specifically, a single vaccination with BPZE1 prevented 90
8-K
EX-99.1
NTIP
Network-1 Technologies Inc
20 Dec 18
Other Events
3:40pm
of Allergy and Infectious Disease (NIAID) at the National Institute of Health (NIH). BPZE1 has previously successfully demonstrated safety and immunological
8-K
EX-99.1
NTIP
Network-1 Technologies Inc
17 May 19
NETWORK-1 Reports First Quarter 2019 Results
2:34pm
) and 60% (additional $1,500,000 investment by Network-1) would be due when ILiAD receives satisfactory safety data from the clinical study
S-8
s1if6arj
28 Jun 01
Registration of securities for employees
12:00am
S-3
8f594ij
4 Feb 00
Shelf registration
12:00am